MOREPEN LABS share price has zoomed 6% and is presently trading at Rs 90.8.
Meanwhile, the BSE HEALTHCARE index is at 44,459.9 (up 0.5%).
Among the top gainers in the BSE HEALTHCARE index today are ASTRAZENECA PHARMA (up 10.3%) and MAX HEALTHCARE INSTITUTE (up 4.4%).
LAURUS LABS (down 1.1%) and ALEMBIC PHARMA (down 1.1%) are among the top losers today.
Over the last one year, MOREPEN LABS has moved up from Rs 36.7 to Rs 90.8, registering a gain of Rs 54.1 (up 147.3%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,349.9 to 44,459.9, registering a gain of 56.8% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 177.9%), SUVEN PHARMACEUTICALS (up 128.8%) and Glenmark Pharma (up 99.7%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 84,916.7 .
The top losers among the BSE Sensex today are Bajaj Finance (down 1.4%) and Hindustan Unilever (down 1.2%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 25,936.8 . Bajaj Finance and Hindustan Unilever are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,800.8 to 84,916.7, registering a gain of 18,115.8 points (up 27.1%).
MOREPEN LABS net profit grew 147.2% YoY to Rs 362 million for the quarter ended June 2024, compared to a profit of Rs 146 million a year ago. Net sales rose 13.5% to Rs 4,552 million during the period as against Rs 4,010 million in April-June 2023.
For the year ended March 2024, MOREPEN LABS reported 149.8% increase in net profit to Rs 966 million compared to net profit of Rs 387 million during FY23. Revenue of the company grew 19.3% to Rs 16,904 million during FY24.
The current Price to earnings ratio of MOREPEN LABS, based on rolling 12 month earnings, stands at 42.1.
Equitymaster requests your view! Post a comment on "MOREPEN LABS Gains 6%; BSE HEALTHCARE Index Up 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!